Aarti Drugs Limited (AARTIDRUGS.BO)
INR 330.65
(2.85%)
INR 330.65
(2.85%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 5.54 Billion INR | -7.52% |
| 2022 | 5.99 Billion INR | 15.11% |
| 2021 | 5.21 Billion INR | 52.42% |
| 2020 | 3.41 Billion INR | -10.45% |
| 2019 | 3.81 Billion INR | -24.02% |
| 2018 | 5.02 Billion INR | -7.44% |
| 2017 | 5.42 Billion INR | 13.98% |
| 2016 | 4.76 Billion INR | -0.72% |
| 2015 | 4.79 Billion INR | 7.78% |
| 2014 | 4.45 Billion INR | 18.74% |
| 2013 | 3.74 Billion INR | 17.85% |
| 2012 | 3.18 Billion INR | 8.44% |
| 2011 | 2.93 Billion INR | 11.88% |
| 2010 | 2.62 Billion INR | 45.43% |
| 2009 | 1.8 Billion INR | -4.46% |
| 2008 | 1.88 Billion INR | -11.45% |
| 2007 | 2.13 Billion INR | 9.86% |
| 2006 | 1.94 Billion INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 5.76 Billion INR | 2686.52% |
| 2024 Q1 | 207.7 Million INR | -96.26% |
| 2023 Q4 | 5.54 Billion INR | 2120.25% |
| 2023 FY | 5.54 Billion INR | -7.52% |
| 2023 Q1 | 211.7 Million INR | -96.47% |
| 2023 Q2 | 5.76 Billion INR | 2622.63% |
| 2023 Q3 | 249.9 Million INR | -95.66% |
| 2022 Q2 | 5.71 Billion INR | 1560.96% |
| 2022 FY | 5.99 Billion INR | 15.11% |
| 2022 Q3 | 272.3 Million INR | -95.23% |
| 2022 Q4 | 5.99 Billion INR | 2103.27% |
| 2022 Q1 | 343.8 Million INR | -93.4% |
| 2021 Q1 | 225 Million INR | -93.42% |
| 2021 Q2 | 4.63 Billion INR | 1960.8% |
| 2021 Q3 | 199.1 Million INR | -95.71% |
| 2021 Q4 | 5.21 Billion INR | 2517.8% |
| 2021 FY | 5.21 Billion INR | 52.42% |
| 2020 Q2 | 3.27 Billion INR | 1568.84% |
| 2020 Q4 | 3.41 Billion INR | 1389.31% |
| 2020 FY | 3.41 Billion INR | -10.45% |
| 2020 Q1 | 196.4 Million INR | -94.86% |
| 2020 Q3 | 229.6 Million INR | -92.99% |
| 2019 Q4 | 3.81 Billion INR | 2032.15% |
| 2019 Q2 | 4.32 Billion INR | 2888.81% |
| 2019 Q1 | 144.77 Million INR | -97.12% |
| 2019 Q3 | 179.1 Million INR | -95.86% |
| 2019 FY | 3.81 Billion INR | -24.02% |
| 2018 Q4 | 5.02 Billion INR | 5777.99% |
| 2018 Q2 | 5.09 Billion INR | 3701.28% |
| 2018 FY | 5.02 Billion INR | -7.44% |
| 2018 Q1 | 134 Million INR | -97.34% |
| 2018 Q3 | 85.5 Million INR | -98.32% |
| 2017 Q2 | 4.79 Billion INR | 3826.66% |
| 2017 Q1 | 122 Million INR | -97.44% |
| 2017 FY | 5.42 Billion INR | 13.98% |
| 2017 Q4 | 5.04 Billion INR | 1132.75% |
| 2017 Q3 | 408.9 Million INR | -91.46% |
| 2016 Q3 | 25.8 Million INR | -99.37% |
| 2016 FY | 4.76 Billion INR | -0.72% |
| 2016 Q4 | 4.76 Billion INR | 18363.14% |
| 2016 Q2 | 4.08 Billion INR | 3121.96% |
| 2016 Q1 | 126.89 Million INR | -97.36% |
| 2015 Q4 | 4.79 Billion INR | 13302.41% |
| 2015 FY | 4.79 Billion INR | 7.78% |
| 2015 Q1 | 92.75 Million INR | -97.92% |
| 2015 Q2 | 4.74 Billion INR | 5015.36% |
| 2015 Q3 | 35.8 Million INR | -99.25% |
| 2014 Q3 | 23.3 Million INR | -99.41% |
| 2014 Q2 | 3.92 Billion INR | 4582.65% |
| 2014 Q1 | 83.91 Million INR | -97.76% |
| 2014 Q4 | 4.45 Billion INR | 19006.36% |
| 2014 FY | 4.45 Billion INR | 18.74% |
| 2013 FY | 3.74 Billion INR | 17.85% |
| 2013 Q1 | 65.13 Million INR | -97.95% |
| 2013 Q4 | 3.74 Billion INR | 17338.17% |
| 2013 Q2 | 3.23 Billion INR | 4870.11% |
| 2013 Q3 | 21.5 Million INR | -99.34% |
| 2012 Q2 | 1.06 Billion INR | 0.0% |
| 2012 FY | 3.18 Billion INR | 8.44% |
| 2012 Q4 | 3.18 Billion INR | 0.0% |
| 2011 FY | 2.93 Billion INR | 11.88% |
| 2010 FY | 2.62 Billion INR | 45.43% |
| 2009 FY | 1.8 Billion INR | -4.46% |
| 2008 FY | 1.88 Billion INR | -11.45% |
| 2007 FY | 2.13 Billion INR | 9.86% |
| 2006 FY | 1.94 Billion INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | -43.522% |
| Aurobindo Pharma Limited | 3.69 Billion INR | -50.229% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 295.183% |
| Granules India Limited | 9.28 Billion INR | 40.255% |
| Indoco Remedies Limited | 6.47 Billion INR | 14.328% |
| Achyut Healthcare Limited | -3.74 Million INR | 148215.323% |
| Ajanta Pharma Limited | -954.9 Million INR | 681.045% |
| Alkem Laboratories Limited | -1.6 Billion INR | 444.75% |
| Alpa Laboratories Limited | 35.36 Million INR | -15589.845% |
| Brooks Laboratories Limited | 49.48 Million INR | -11112.287% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 210.693% |
| Bajaj HealthCare Limited | 3.29 Billion INR | -68.187% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 579.239% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 57.032% |
| Eris Lifesciences Limited | 13.8 Billion INR | 59.813% |
| FDC Limited | -57.75 Million INR | 9707.286% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 229.476% |
| Gufic Biosciences Limited | 3.19 Billion INR | -73.696% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 233.598% |
| Ipca Laboratories Limited | 11.41 Billion INR | 51.395% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 499.186% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -187.047% |
| Lasa Supergenerics Limited | 205.79 Million INR | -2596.029% |
| Laurus Labs Limited | 24.38 Billion INR | 77.246% |
| Lupin Limited | 17.19 Billion INR | 67.727% |
| Mankind Pharma Limited | -9.9 Billion INR | 155.999% |
| Medicamen Biotech Limited | 160.31 Million INR | -3360.915% |
| Medico Remedies Limited | 78.67 Million INR | -6952.125% |
| Megasoft Limited | 1.28 Billion INR | -331.597% |
| NATCO Pharma Limited | -5.81 Billion INR | 195.382% |
| Piramal Pharma Limited | 42.27 Billion INR | 86.876% |
| RPG Life Sciences Limited | -364.7 Million INR | 1621.36% |
| Sigachi Industries Limited | 859.94 Million INR | -545.201% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 107.656% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -3727.116% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -11906.665% |
| Unichem Laboratories Limited | 931.91 Million INR | -495.376% |
| Wanbury Limited | 1.1 Billion INR | -401.72% |
| Windlas Biotech Limited | -273.04 Million INR | 2132.083% |
| ZIM Laboratories Limited | 983.6 Million INR | -464.089% |
| Zydus Lifesciences Limited | 3.91 Billion INR | -41.83% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 689.127% |
| Divi's Laboratories Limited | -39.77 Billion INR | 113.951% |
| Hester Biosciences Limited | 2.29 Billion INR | -142.21% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 336.303% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 2330.136% |
| Bal Pharma Limited | 1.26 Billion INR | -339.108% |
| Strides Pharma Science Limited | 23.25 Billion INR | 76.143% |
| Venus Remedies Limited | -267.7 Million INR | 2172.619% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | -112.428% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 9.889% |
| Shilpa Medicare Limited | 9.06 Billion INR | 38.824% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 603.805% |
| Suven Life Sciences Limited | -1.63 Billion INR | 439.83% |
| Ind-Swift Limited | 9.5 Billion INR | 41.649% |
| Valiant Laboratories Limited | -295.03 Million INR | 1980.61% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | -96.668% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 44.676% |
| Themis Medicare Limited | 764.96 Million INR | -625.317% |
| Hikal Limited | 7.96 Billion INR | 30.358% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 82.569% |
| Sequent Scientific Limited | 4.17 Billion INR | -32.78% |
| Novartis India Limited | -5.89 Billion INR | 194.183% |
| Wockhardt Limited | 18.27 Billion INR | 69.631% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 79.505% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 30179.15% |
| Neuland Laboratories Limited | -214.05 Million INR | 2692.008% |
| Morepen Laboratories Limited | -231.17 Million INR | 2500.097% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -4522.164% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | -468.594% |